| Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective … W De Roock, B Claes, D Bernasconi, J De Schutter, B Biesmans, ... The lancet oncology 11 (8), 753-762, 2010 | 1979 | 2010 |
| A controlled-release microchip JT Santini, MJ Cima, R Langer Nature 397 (6717), 335-338, 1999 | 995 | 1999 |
| KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer F Loupakis, A Ruzzo, C Cremolini, B Vincenzi, L Salvatore, D Santini, ... British journal of cancer 101 (4), 715-721, 2009 | 565 | 2009 |
| Management of cancer pain: ESMO clinical practice guidelines CI Ripamonti, D Santini, E Maranzano, M Berti, F Roila, ... Annals of oncology 23 (suppl_7), vii139-vii154, 2012 | 481 | 2012 |
| PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer F Loupakis, L Pollina, I Stasi, A Ruzzo, M Scartozzi, D Santini, G Masi, ... Journal of clinical oncology 27 (16), 2622-2629, 2009 | 466 | 2009 |
| Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients D Santini, B Vincenzi, G Dicuonzo, G Avvisati, C Massacesi, F Battistoni, ... Clinical Cancer Research 9 (8), 2893-2897, 2003 | 366 | 2003 |
| Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy A Ruzzo, F Graziano, F Loupakis, E Rulli, E Canestrari, D Santini, ... Journal of clinical oncology 25 (10), 1247-1254, 2007 | 342 | 2007 |
| Pamidronate induces modifications of circulating angiogenetic factors in cancer patients D Santini, B Vincenzi, G Avvisati, G Dicuonzo, F Battistoni, M Gavasci, ... Clinical Cancer Research 8 (5), 1080-1084, 2002 | 318 | 2002 |
| High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice D Santini, F Loupakis, B Vincenzi, I Floriani, I Stasi, E Canestrari, E Rulli, ... The oncologist 13 (12), 1270-1275, 2008 | 263 | 2008 |
| Tissue invasion and metastasis: Molecular, biological and clinical perspectives WG Jiang, AJ Sanders, M Katoh, H Ungefroren, F Gieseler, M Prince, ... Seminars in cancer biology 35, S244-S275, 2015 | 260 | 2015 |
| PD-1 blockade therapy in renal cell carcinoma: current studies and future promises F Massari, M Santoni, C Ciccarese, D Santini, S Alfieri, G Martignoni, ... Cancer treatment reviews 41 (2), 114-121, 2015 | 217 | 2015 |
| The antineoplastic role of bisphosphonates: from basic research to clinical evidence D Santini, U Vespasiani Gentilucci, B Vincenzi, A Picardi, F Vasaturo, ... Annals of Oncology 14 (10), 1468-1476, 2003 | 200 | 2003 |
| Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in … D Santini, B Vincenzi, S Galluzzo, F Battistoni, L Rocci, O Venditti, ... Clinical Cancer Research 13 (15), 4482-4486, 2007 | 192 | 2007 |
| Intratumoural FOXP3-positive regulatory T cells are associated with adverse prognosis in radically resected gastric cancer G Perrone, PA Ruffini, V Catalano, C Spino, D Santini, P Muretto, C Spoto, ... European journal of cancer 44 (13), 1875-1882, 2008 | 191 | 2008 |
| Pharmacogenetic profiling and clinical outcome of patients with advanced gastric cancer treated with palliative chemotherapy A Ruzzo, F Graziano, K Kawakami, G Watanabe, D Santini, V Catalano, ... J Clin Oncol 24 (12), 1883-1891, 2006 | 179 | 2006 |
| Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib B Vincenzi, D Santini, A Russo, R Addeo, F Giuliani, L Montella, S Rizzo, ... The oncologist 15 (1), 85, 2010 | 177 | 2010 |
| Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients B Vincenzi, D Santini, G Dicuonzo, F Battistoni, M Gavasci, A La Cesa, ... Journal of interferon & cytokine research 25 (3), 144-151, 2005 | 168 | 2005 |
| Receptor activator of NF-kB (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patients D Santini, G Schiavon, B Vincenzi, L Gaeta, F Pantano, A Russo, ... PloS one 6 (4), 2011 | 161 | 2011 |
| Designing a broad-spectrum integrative approach for cancer prevention and treatment KI Block, C Gyllenhaal, L Lowe, A Amedei, ARMR Amin, A Amin, ... Seminars in cancer biology 35, S276-S304, 2015 | 153 | 2015 |
| Emerging anti-cancer molecular mechanisms of aminobisphosphonates M Caraglia, D Santini, M Marra, B Vincenzi, G Tonini, A Budillon Endocrine-related cancer 13 (1), 7-26, 2006 | 148 | 2006 |
